OakChart

Taysha Gene Therapies Inc

TSHAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:17 AM ET

4.25-0.03 (-0.58%)
2026-11-11 16:18 CET
Market cap
1,392.94 USD m
Revenue, TTM
5.49 USD m
Net income, TTM
-149.63 USD m
Free cash flow, TTM
-132.57 USD m
EPS diluted, TTM
-0.43
P/E
-
Compare

Price

TSHA against its 20, 50 and 200-day averages
2050200earnings
4.005.006.007.005.9M11.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TSHAclose 4.2520-day 4.1050-day 4.55200-day 5.304.25

41.8% under 7.30 on 6 May 2026. Last 15 sessions, 20.6% high to low

Profile

TSHA
52-week range, 21% of the way up
3.457.30

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

IndexRUT
Employees99
IPOSep 24, 2020
Beta1.31
ATR, 14d0.27
Rel volume0.51
Short float19.49%
Insider own15.79%
Inst own86.86%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.38B
Enterprise Value986.26M
Income-149.63M
Sales5.49M
Book/sh1.19
Cash/sh1.40
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees99
IPOSep 24, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S252.24
P/B3.57
P/C3.04
P/FCF-
EV/EBITDA-
EV/Sales179.65
Quick Ratio17.76
Current Ratio17.76
Debt/Eq0.15
LT Debt/Eq0.14
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.43
EPS next Y-0.52
EPS next Q-0.13
EPS this Y-46.61%
EPS next Y-5.03%
EPS next 5Y10.86%
EPS past 3/5Y55.14% 36.86%
Sales past 3/5Y57.49% -
EPS Y/Y TTM-21.09%
Sales Y/Y TTM-32.27%
EPS Q/Q-40.13%
Sales Q/Q-100.00%
EarningsNov 12 BMO
EPS/Sales Surpr.-14.74% -100.00%

Ownership

Insider Own15.79%
Insider Trans-0.39%
Inst Own86.86%
Inst Trans9.93%
ROA-37.23%
ROE-47.05%
ROIC-33.79%
Gross Margin78.65%
Oper. Margin-2854.91%
Profit Margin-2728.04%
SMA203.54%
SMA50-6.58%
SMA200-19.86%
Trades-

Technical

Shs Outstand325.30M
Shs Float274.37M
Short Float19.49%
Short Ratio14.76
Short Interest53.48M
52W High7.30 -41.78%
52W Low3.45 23.01%
Volatility7.94% 7.27%
ATR (14)0.27
RSI (14)48.92
Beta1.31
Rel Volume0.51
Avg Volume3.62M
Volume304,954

Performance

Perf Week-2.52%
Perf Month18.72%
Perf Quarter-29.05%
Perf Half Y-36.28%
Perf YTD-22.73%
Perf Year-0.70%
Perf 3Y182.39%
Perf 5Y-71.67%
Perf 10Y-
Recom1.08
Target Price13.00
Prev Close4.28
Price4.25
Change %-0.58%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 17, 2026InitiatedWWolfe ResearchOutperform
Oct 21, 2025InitiatedRRaymond JamesStrong Buy$13+205.9%
Jul 11, 2025InitiatedBBofA SecuritiesBuy$8+88.2%
Jun 27, 2024InitiatedBBMO Capital MarketsOutperform$5+17.6%
Apr 09, 2024InitiatedPPiper SandlerOverweight$9+111.8%
Feb 01, 2023DowngradeJJefferiesBuy → Hold$14 → $1.50-64.7%
Jan 27, 2023DowngradeMMorgan StanleyOverweight → Equal-Weight$23 → $3-29.4%
Nov 09, 2022DowngradeGGoldmanBuy → Neutral$16 → $3-29.4%
Mar 09, 2022InitiatedRRobert W. BairdOutperform$26+511.8%
Mar 01, 2022InitiatedWWells FargoOverweight$25+488.2%

Peers

Mkt cap
TickerCompanyMkt cap
NGNENeurogene Inc525.29M
ACADAcadia Pharmaceuticals Inc3.17B
QUREuniQure NV1.61B
SRPTSarepta Therapeutics Inc1.75B
RGNXRegenxbio Inc542.20M
STOKStoke Therapeutics Inc1.77B
SLDBSolid Biosciences Inc834.29M
VYGRVoyager Therapeutics Inc111.08M
ABEOAbeona Therapeutics Inc139.16M
RCKTRocket Pharmaceuticals Inc267.81M

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Nagendran SukumarPresident and Head of R&DJul 10 '26Sale6.24200,0001,248,000936,410Jul 10 06:54 PM
Nagendran SukumarOfficerJul 10 '26Proposed Sale6.49200,0001,298,000Jul 10 04:21 PM
Nagendran SukumarPresident and Head of R&DApr 10 '26Option Exercise1.7119,02132,5261,336,410Apr 13 04:33 PM
Nagendran SukumarPresident and Head of R&DApr 10 '26Sale4.46200,000892,0001,136,410Apr 13 04:33 PM
Nagendran SukumarOfficerApr 10 '26Proposed Sale4.63200,000926,000Apr 10 04:11 PM
Rumana Haque-AhmedOfficerFeb 27 '26Proposed Sale4.572,40510,991Feb 27 04:07 PM
Alam KamranCHIEF FINANCIAL OFFICERFeb 04 '26Sale4.521,6557,4811,442,131Feb 06 04:30 PM
Emily McGinnisAffiliate-Chief Pat. Adv. &ampFeb 04 '26Proposed Sale4.729014,253Feb 04 06:44 PM
Fred PorterAffiliate-Chief of Staff &Feb 04 '26Proposed Sale4.728894,196Feb 04 06:42 PM
Sean McAuliffeAffiliate - Chief Business OffFeb 04 '26Proposed Sale4.729144,314Feb 04 06:41 PM
Rumana Haque-AhmedOfficerFeb 04 '26Proposed Sale4.726973,290Feb 04 06:39 PM
Kamran AlamOfficerFeb 04 '26Proposed Sale4.721,6557,812Feb 04 06:38 PM
Nagendran SukumarPresident and Head of R&DJan 23 '26Sale4.7589,132423,3771,344,307Jan 27 04:05 PM
Nagendran SukumarPresident and Head of R&DJan 26 '26Sale4.6126,918124,0921,317,389Jan 27 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 206
  • Taysha Heads Into Q3 With Pivotal Dosing Done, A Fat Cash Cushion And A Stock Down A Third (Earnings Whispers) +5.87%
  • Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 (GlobeNewswire) -6.19%
  • Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting (GlobeNewswire)
  • Loading…
  • Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... (GuruFocus.com)
  • Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 (GlobeNewswire) +7.27%
  • Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome (GlobeNewswire)
  • Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting (GlobeNewswire) -10.52%
  • Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.129--0.7613
2026Q22026-08-11-0.130-0.113-0.1240.000.6812
2026Q12026-05-06-0.120-0.097-0.1160.000.7612
2025Q42026-03-19-0.080-0.096-0.0985.482.2414
2025Q32025-11-04-0.090-0.089-0.0930.291.4314
2025Q22025-08-12-0.090-0.078-0.0901.991.6713
2025Q12025-05-15-0.080-0.088-0.0802.301.8712
2024Q42025-02-26-0.070-0.081-0.0922.022.1412
2024Q32024-11-13-0.100-0.087-0.0951.791.7412
2024Q22024-08-12-0.090-0.157-0.0901.112.7612
2024Q12024-05-14-0.100-0.107-0.1043.412.8811
2023Q42024-03-190.255-0.1100.2553.642.9510
2023Q32023-11-14-0.930-0.173-0.9324.752.3310
2023Q22023-08-14-0.380-0.311-0.3832.402.409
2023Q12023-05-11-0.280-0.354-0.2794.711.8010
2022Q42023-03-28-0.990-0.399-0.9882.5011.2512

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-3.400-2.525-3.3970.000.00
2021FY-4.640-4.551-4.6350.000.00
2022FY-3.780-2.944-3.7772.508.18
2023FY-0.960-1.468-0.96115.5014.49
2024FY-0.360-0.370-0.3578.338.25
2025FY-0.340-0.360-0.3409.775.87
2026FY--0.499--1.91
2027FY--0.524--28.47
2028FY--0.241--158.41
2029FY-0.348--540.35
2030FY-1.066--1,038

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-129000.760.003.80
2026Q3S2026-08-119000.760.003.80
2026Q3S2026-07-309000.760.003.80
2026Q3S2026-07-0110000.680.003.80
2026Q3S2026-06-029000.330.002.00
2026Q3S2026-05-089010.330.002.00
2026Q3S2026-05-068010.380.002.00
2026Q3S2026-04-029010.760.003.80
2026Q3S2026-03-198010.850.003.80
2026Q3S2025-11-117001.300.003.80
2026Q3S2025-11-107001.300.003.80
2026Q3S2025-11-097001.300.003.80
2026Q3S2025-11-087001.300.003.80
2026Q3S2025-11-077001.300.003.80

Estimate history

EPS, annual-0.03-3.397-4.635-3.777-0.961-0.357-0.341-0.4324
Period2019202020212022202320242025TTM
EPS, quarterly-0.09-0.095-0.092-0.08-0.09-0.093-0.098-0.116-0.126
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0002.50215.4518.3339.7735.49
Period2019202020212022202320242025TTM
Sales, quarterly1.1121.7882.0222.3021.98605.48500
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual36.99237.76138.47463.208186.96204.943285.052325.302
Period2019202020212022202320242025MRQ
Shares, quarterly201.381204.943204.943205.055272.73273.915285.052287.277325.302
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue5.499.778.3315.452.500.000.000.00
Cost of Goods Sold Incl. D&A1.171.151.251.372.490.490.010.00
Gross Profit4.318.637.0914.080.01-0.49-0.010.00
Selling, General and Administrative Excl. Other160.91119.1393.7185.45126.04172.7842.991.11
Research and Development121.9786.4066.0056.7891.17131.9431.890.99
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-156.59-110.50-86.62-71.37-126.03-173.27-43.00-1.11
Interest Expense0.040.060.105.003.801.430.030.00
Unusual Expense7.207.379.4038.7236.420.0017.030.00
Net Income Before Taxes-149.63-109.00-89.30-111.57-166.01-174.52-60.01-1.11
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-149.63-109.00-89.30-111.57-166.01-174.52-60.01-1.11
Net Income From Continuing Operations-149.63-109.00-89.30-111.57-166.01-174.52-60.01-1.11
Net Income-149.63-109.00-89.30-111.57-166.01-174.52-60.01-1.11
EPS (Recurring)-0.39-0.32-0.33-0.73-3.20-4.64-2.72-0.03
EPS (Basic, Before Extraordinaries)-0.43-0.34-0.36-0.96-3.78-4.64-3.40-0.03
EPS (Diluted)-0.43-0.34-0.36-0.96-3.78-4.64-3.40-0.03
EBITDA-155.42-109.35-85.38-70.00-123.54-172.78-42.99-1.11
Non-Operating Income (Expense)14.208.936.833.520.230.170.050.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.8913.3013.107.9118.0418.183.35-
Price To Sales Ratio458.19179.9351.9313.3039.70---
Gross Margin78.6588.2885.0691.130.60---
Operating Margin-2,854.91-1,130.65-1,039.49-461.94-5,037.05---
Net Margin-2,728.04-1,115.27-1,071.62-722.06-6,635.25---
Shares Outstanding325.30285.05204.94186.9663.2138.4737.7636.99
Market Capitalization1,392.941,392.94354.55330.92141.12448.221,002.191,030.13

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.005.490.001.992.302.021.79
Cost of Goods Sold Incl. D&A0.290.290.300.290.280.280.300.30
Gross Profit-0.29-0.295.19-0.291.712.021.721.49
Selling, General and Administrative Excl. Other50.4943.1933.4933.7428.4623.4421.6522.55
Research and Development38.3433.5124.6525.4619.8615.2815.3214.95
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-50.78-43.49-28.30-34.02-26.75-21.42-19.93-21.06
Interest Expense0.010.010.010.010.020.020.020.02
Unusual Expense1.521.472.381.831.731.430.471.63
Net Income Before Taxes-46.64-42.41-27.85-32.73-26.88-21.53-18.79-25.52
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-46.64-42.41-27.85-32.73-26.88-21.53-18.79-25.52
Net Income From Continuing Operations-46.64-42.41-27.85-32.73-26.88-21.53-18.79-25.52
Net Income-46.64-42.41-27.85-32.73-26.88-21.53-18.79-25.52
EPS (Recurring)-0.12-0.11-0.09-0.09-0.09-0.08-0.09-0.09
EPS (Basic, Before Extraordinaries)-0.13-0.12-0.10-0.09-0.09-0.08-0.09-0.10
EPS (Diluted)-0.13-0.12-0.10-0.09-0.09-0.08-0.09-0.10
EBITDA-50.49-43.19-28.00-33.74-26.48-21.14-19.63-20.76
Non-Operating Income (Expense)5.672.562.843.131.621.341.63-2.81
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.815.553.530.003.193.293.223.36
Price To Sales Ratio458.19219.36160.42183.0985.0051.8242.5554.29
Gross Margin--94.55-86.0587.7184.9783.22
Operating Margin---515.95--1,347.08-930.54-985.76-1,177.85
Net Margin---507.77--1,353.58-935.23-929.03-1,427.52
Shares Outstanding325.30287.28285.05273.92272.73205.05204.94204.94
Market Capitalization1,392.941,284.101,506.55892.04604.13284.95354.55411.94

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments320.22139.49144.3987.88149.10251.250.00
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets4.242.514.807.819.956.630.00
Total Current Assets324.45142.00149.1995.69159.06257.880.00
Net Property, Plant & Equipment16.1815.8720.4125.9150.610.290.00
Total Investments and Advances2.312.152.152.642.640.000.00
Intangible Assets------0.00
Deferred Tax Assets140.41116.0494.262.35---
Other Assets0.380.350.982.041.650.710.01
Total Assets483.73276.41266.99128.63213.96258.880.01
Short Term Debt Incl. Current Port. of LT Debt2.242.271.651.520.000.000.00
Accounts Payable6.283.596.3710.950.000.000.00
Other Current Liabilities18.0320.3728.7450.3251.757.130.15
Total Current Liabilities26.5526.2336.7662.7951.757.130.15
Long Term Debt68.2861.6859.4658.4163.090.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities140.41116.0494.262.35---
Other Liabilities1.550.931.584.133.730.450.00
Total Liabilities236.79204.88192.06127.68118.577.580.15
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity246.9471.5374.940.9595.38251.30-0.14
Total Shareholders Equity246.9471.5374.940.9595.38251.30-0.14
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity246.9471.5374.940.9595.38251.30-0.14
Total Liabilities & Stockholders Equity483.73276.41266.99128.63213.96258.880.01
Book Value Per Share0.870.350.400.022.486.65-0.00
Tangible Book Value Per Share0.870.350.400.022.486.65-0.00
Full-Time Employees9973526517838-
Price to Book Ratio3.593.99-6.748.364.703.993.85
Return on Assets-28.68-32.87-56.40-96.92-73.82-46.36-
Return on Equity-68.45-121.94-294.04-344.67-100.68-47.79-
Return on Invested Capital-34.58-67.04-83.01-279.69-110.13-23.88-
Quick Ratio12.225.414.061.523.0736.170.00
Current Ratio12.225.414.061.523.0736.170.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-149.63-109.00-89.30-111.57-166.01-174.52-60.01-1.11
Depreciation1.171.151.251.372.490.490.01-
Other Funds (Non Cash)19.2020.1319.3055.1956.6228.3229.380.98
Funds from Operations-129.27-87.72-68.76-55.01-106.91-145.71-30.62-0.14
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-2.92-5.37-12.47-18.0118.5228.67-0.110.14
Cash from Operating Activities-132.19-93.09-81.22-73.02-88.39-117.04-30.730.00
Capital Expenditures-3.38-0.74-0.37-7.37-24.87-21.55-9.080.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.00-0.060.000.000.00
Other Sources0.060.130.010.020.000.000.000.00
Cash from Investing Activities-3.32-0.60-0.36-7.35-24.93-21.55-9.080.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock266.71265.6976.87140.4753.14-0.36291.060.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock266.71265.6976.87140.4753.14-0.36291.060.00
Proceedsfrom Stock Options0.000.0076.87140.4753.14-0.36291.060.00
Issuance or Reduction of Debt, Net9.249.240.00-3.850.0039.960.000.00
Change in Long Term Debt9.249.240.00-3.850.0039.960.000.00
Issuance of Long Term Debt49.8549.850.0039.150.0039.960.000.00
Reduction of Long Term Debt-40.61-40.610.00-43.000.000.000.000.00
Net Financing Active Other Cash Flow-0.23-0.34-0.17-0.23-1.04-0.510.000.00
Other Financing Activities Uses-0.29-0.34-0.17-0.23-1.04-0.510.000.00
Cash from Financing Activities275.72274.5976.68136.3952.1039.08291.060.00
Net Change in Cash140.21180.90-4.9056.02-61.22-99.51251.250.00
Free Cash Flow-132.57-93.83-81.60-76.89-109.01-132.35-30.810.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments455.41277.02320.22297.79313.21117.04
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets5.925.034.242.103.023.53
Total Current Assets461.32282.06324.45299.89316.23120.57
Net Property, Plant & Equipment8.7315.6116.1814.2714.7315.31
Total Investments and Advances0.162.312.312.152.152.15
Deferred Tax Assets--140.41---
Other Assets0.220.380.380.240.220.33
Total Assets470.43300.35483.73316.55333.33138.36
Short Term Debt Incl. Current Port. of LT Debt1.332.102.242.092.152.21
Accounts Payable9.164.566.285.447.714.33
Other Current Liabilities15.4813.4418.0321.1015.4916.02
Total Current Liabilities25.9820.1026.5528.6325.3522.56
Long Term Debt55.5566.7368.2867.4258.0359.82
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--140.41---
Other Liabilities1.641.581.551.521.230.93
Total Liabilities83.1788.41236.7997.5684.6083.30
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity387.27211.94246.94218.99248.7355.06
Total Shareholders Equity387.27211.94246.94218.99248.7355.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity387.27211.94246.94218.99248.7355.06
Total Liabilities & Stockholders Equity470.43300.35483.73316.55333.33138.36
Book Value Per Share1.190.740.870.800.910.27
Tangible Book Value Per Share1.190.740.870.800.910.27
Full-Time Employees--99---
Price to Book Ratio3.595.166.883.598.603.98
Return on Assets-37.23-59.21-28.68-40.23-34.74-59.56
Return on Equity-47.05-97.28-68.45-64.93-51.86-159.34
Return on Invested Capital-10.53-15.22-8.84-11.43-8.76-18.74
Quick Ratio17.7614.0312.2210.4712.485.35
Current Ratio17.7614.0312.2210.4712.485.35

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-46.64-42.41-27.85-32.73-26.88-21.53
Depreciation0.290.290.300.290.280.28
Other Funds (Non Cash)1.155.897.904.254.203.78
Funds from Operations-45.20-36.22-19.65-28.20-22.41-17.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.77-4.65-7.074.032.23-4.56
Cash from Operating Activities-40.42-40.88-26.72-24.17-20.18-22.02
Capital Expenditures0.00-3.02-0.25-0.11-0.00-0.38
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.060.060.01
Cash from Investing Activities0.00-3.02-0.25-0.050.06-0.37
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock216.580.6949.61-0.17216.170.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock216.580.6949.61-0.17216.170.07
Proceedsfrom Stock Options0.000.000.000.00-0.070.07
Issuance or Reduction of Debt, Net0.000.000.009.240.000.00
Change in Long Term Debt0.000.000.009.240.000.00
Issuance of Long Term Debt0.000.000.0049.850.000.00
Reduction of Long Term Debt0.000.000.00-40.610.000.00
Net Financing Active Other Cash Flow0.070.02-0.06-0.270.12-0.13
Other Financing Activities Uses0.000.00-0.06-0.230.08-0.13
Cash from Financing Activities216.660.7149.568.80216.29-0.05
Net Change in Cash176.23-43.1922.59-15.42196.17-22.44
Free Cash Flow-40.42-40.90-26.97-24.27-20.18-22.40

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 8.33M 2025: 9.77M
United States2024: 8.33M 2025: 9.77M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.49%53.5M274.4M3.52M
2026-10-1518.68%51.2M274.4M3.32M
2026-09-3020.05%55.0M274.4M3.14M
2026-09-1518.74%51.4M274.4M3.15M
2026-08-3117.70%46.8M264.4M3.11M
2026-08-1417.68%46.7M264.4M3.10M
2026-07-3117.61%46.7M265.1M3.04M
2026-07-1517.08%45.3M265.1M3.12M
2026-06-3015.39%41.4M269.1M3.02M
2026-06-1516.49%38.7M234.9M2.71M
2026-05-2915.13%36.0M238.0M2.78M
2026-05-1515.42%36.7M238.1M2.79M
2026-04-3017.00%40.1M235.6M2.77M
2026-04-1516.52%38.9M235.5M2.74M
2026-03-3117.96%42.3M235.3M2.76M
2026-03-1319.71%46.4M235.3M2.79M
2026-02-2722.14%49.7M224.4M2.85M
2026-02-1321.82%49.0M224.4M3.04M
2026-01-3025.46%55.7M218.8M3.38M
2026-01-1526.03%56.8M218.4M3.58M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.002.803.800.0015.7490.000.000.966-0.0440.001
call2.001.902.900.008.2690.000.000.910-0.0710.001
call3.000.851.850.004.8800.000.000.808-0.0720.002
call4.000.101.100.553.8398780.000.663-0.0570.002
call5.000.000.400.152.4971620.000.411-0.0360.003
call6.000.001.000.373.16099.000.000.348-0.0420.003
call7.000.001.000.053.9871,5030.000.314-0.0520.002
call8.000.000.100.004.2640.000.000.293-0.0530.002
call9.000.001.000.003.2840.000.000.115-0.0230.001
call10.000.001.000.005.0170.000.000.268-0.0590.002
put1.000.000.050.000.0000.000.00-0.036-0.0440.001
put2.000.001.000.003.2190.000.00-0.044-0.0110.001
put3.000.001.000.001.7280.000.00-0.081-0.0090.001
put4.000.001.000.254.3875750.00-0.337-0.0570.002
put5.000.401.400.953.18072.000.00-0.590-0.0350.003
put6.001.352.350.003.8680.000.00-0.654-0.0450.002
put7.002.203.200.004.1400.000.00-0.686-0.0510.002
put8.003.204.200.005.0080.000.00-0.707-0.0520.002
put9.004.305.300.005.0530.000.00-0.885-0.0220.001
put10.005.306.300.005.4190.000.00-0.892-0.0230.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-10144Filing for proposed sale of securities under Rule 144.SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-06-258-KCurrent report2026-06-24SEC
2026-06-25424B5SEC
2026-06-24424B5SEC
2026-06-228-KCurrent report2026-06-22SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-028-KCurrent report2026-06-01SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-04-22ARSAnnual report to security holders. 2025-12-31SEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-01SEC
2026-04-134Statement of changes in beneficial ownership of securities2026-04-10SEC
2026-04-10144Filing for proposed sale of securities under Rule 144.SEC
2026-03-1910-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-198-KCurrent report2026-03-19SEC
2026-02-27144Filing for proposed sale of securities under Rule 144.SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-17SCHEDULE 13GSEC
2026-02-064Statement of changes in beneficial ownership of securities2026-02-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07001.25M1
2026-060000
2026-050000
2026-0400892.00K1
2026-030000
2026-02007.48K1
2026-01002.81M7
2025-12001.17M1
2025-1100523.09K1

Institutional holders

Manager% owned
Avoro Capital Advisors LLC8.31%
RA CAPITAL MANAGEMENT, L.P.8.20%
GOLDMAN SACHS GROUP INC7.90%
BlackRock, Inc.7.20%
Vestal Point Capital, LP6.76%
MORGAN STANLEY5.74%
RTW INVESTMENTS, LP4.72%
VANGUARD CAPITAL MANAGEMENT LLC4.34%
FMR LLC4.16%
STATE STREET CORP3.97%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
iShares Russell 2000 ETF2.17%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.94%
Fidelity Growth Company Fund1.28%
VANGUARD EXTENDED MARKET INDEX FUND1.06%
Fidelity Small Cap Index Fund0.82%
iShares Russell 2000 Growth ETF0.77%
iShares Biotechnology ETF0.59%
abrdn Life Sciences Investors0.52%
VANGUARD RUSSELL 2000 INDEX FUND0.42%

OakChart. TSHA. Cached 15 minutes.